133 related articles for article (PubMed ID: 23757311)
1. Mechanism-based engineering against anthracycline cardiotoxicity.
Force T; Wang Y
Circulation; 2013 Jul; 128(2):98-100. PubMed ID: 23757311
[No Abstract] [Full Text] [Related]
2. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.
Jay SM; Murthy AC; Hawkins JF; Wortzel JR; Steinhauser ML; Alvarez LM; Gannon J; Macrae CA; Griffith LG; Lee RT
Circulation; 2013 Jul; 128(2):152-61. PubMed ID: 23757312
[TBL] [Abstract][Full Text] [Related]
3. Neuregulin-1 attenuates doxorubicin-induced autophagy in neonatal rat cardiomyocytes.
An T; Huang Y; Zhou Q; Wei BQ; Zhang RC; Yin SJ; Zou CH; Zhang YH; Zhang J
J Cardiovasc Pharmacol; 2013 Aug; 62(2):130-7. PubMed ID: 23519142
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition.
Oh J; Lee BS; Lim G; Lim H; Lee CJ; Park S; Lee SH; Chung JH; Kang SM
J Mol Cell Cardiol; 2020 Jan; 138():244-255. PubMed ID: 31866378
[TBL] [Abstract][Full Text] [Related]
5. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
6. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.
Xiao J; Sun GB; Sun B; Wu Y; He L; Wang X; Chen RC; Cao L; Ren XY; Sun XB
Toxicology; 2012 Feb; 292(1):53-62. PubMed ID: 22155320
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
[TBL] [Abstract][Full Text] [Related]
8. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).
Cai C; Lothstein L; Morrison RR; Hofmann PA
J Pharmacol Exp Ther; 2010 Oct; 335(1):223-30. PubMed ID: 20668052
[TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway.
Yang L; Luo C; Chen C; Wang X; Shi W; Liu J
Br J Pharmacol; 2016 Jan; 173(2):357-71. PubMed ID: 26507774
[TBL] [Abstract][Full Text] [Related]
10. Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting reactive oxygen species-activated extracellular signal-regulated kinase 1/2 in H9c2 cardiac myocytes.
Liu MH; Lin XL; Zhang Y; He J; Tan TP; Wu SJ; Liu J; Tian W; Chen L; Yu S; Li J; Yuan C
Mol Med Rep; 2015 Nov; 12(5):6841-8. PubMed ID: 26299281
[TBL] [Abstract][Full Text] [Related]
11. TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.
Kleiner Y; Bar-Am O; Amit T; Berdichevski A; Liani E; Maor G; Reiter I; Youdim MB; Binah O
J Cardiovasc Pharmacol; 2008 Sep; 52(3):268-77. PubMed ID: 18806608
[TBL] [Abstract][Full Text] [Related]
12. Neuregulin-1 protects against doxorubicin-induced apoptosis in cardiomyocytes through an Akt-dependent pathway.
An T; Zhang Y; Huang Y; Zhang R; Yin S; Guo X; Wang Y; Zou C; Wei B; Lv R; Zhou Q; Zhang J
Physiol Res; 2013; 62(4):379-85. PubMed ID: 23590603
[TBL] [Abstract][Full Text] [Related]
13. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.
Li W; Xu B; Xu J; Wu XL
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757
[TBL] [Abstract][Full Text] [Related]
14. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective action of the aqueous extract of Terminalia arjuna bark against toxicity induced by doxorubicin.
Bishop S; Liu SJ
Phytomedicine; 2017 Dec; 36():210-216. PubMed ID: 29157817
[TBL] [Abstract][Full Text] [Related]
16. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol attenuates doxorubicin-induced cardiotoxicity in rats by up-regulation of vascular endothelial growth factor B.
Tian W; Yang L; Liu Y; He J; Yang L; Zhang Q; Liu F; Li J; Liu J; Sumi S; Shen Y; Qi Z
J Nutr Biochem; 2020 May; 79():108132. PubMed ID: 30857673
[TBL] [Abstract][Full Text] [Related]
18. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome Proliferator-Activated Receptor-α Inhibition Protects Against Doxorubicin-Induced Cardiotoxicity in Mice.
Rahmatollahi M; Baram SM; Rahimian R; Saeedi Saravi SS; Dehpour AR
Cardiovasc Toxicol; 2016 Jul; 16(3):244-50. PubMed ID: 26082188
[TBL] [Abstract][Full Text] [Related]
20. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
